All Publications

Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel

Adams ER. et al, (2020), Wellcome Open Research, 5, 139 - 139

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients

DONG T., (2020), BioRxiv

SAMHD1-mediated dNTP degradation is required for efficient DNA repair during antibody class switch recombination.

Husain A. et al, (2020), The EMBO journal

Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.

Zhao Y. et al, (2020), JCI insight

An evidence-based framework for priority clinical research questions for COVID-19.

Harris C. et al, (2020), Journal of global health, 10

A novel scoring system for prediction of disease severity in COVID-19

DONG TAO., (2020), Frontiers in Cellular and Infection Microbiology, section Virus and Host

Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review.

Dagens A. et al, (2020), BMJ (Clinical research ed.), 369

Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient.

Abd Hamid M. et al, (2020), Cellular & molecular immunology

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.

Wang Y. et al, (2020), Trials, 21

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Docherty AB. et al, (2020), BMJ (Clinical research ed.), 369

Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?

Cheung VTF. et al, (2020), British Journal of Cancer

Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009.

Rojek A. et al, (2020)

Inflammatory Bowel Disease Through the Lens of Single-cell RNA-seq Technologies.

Corridoni D. et al, (2020), Inflammatory bowel diseases

Lassa fever in pregnancy: a systematic review and meta-analysis

Kayem ND. et al, (2020), Transactions of The Royal Society of Tropical Medicine and Hygiene, 114, 385 - 396

Longitudinal profiling of cytokines and chemokines in COVID-19 reveals inhibitory mediators IL-1Ra and IL-10 are associated with disease severity while elevated RANTES is an early predictor of mild disease

DONG TAO. et al, (2020), Preprint with Lancet

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Cao B. et al, (2020), The New England journal of medicine, 382, 1787 - 1799

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.

Wang Y. et al, (2020), Lancet (London, England), 395, 1569 - 1578

Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019

Zhang Y. et al, (2020), The Journal of Infectious Diseases

Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

Docherty AB. et al, (2020)

Evaluation of the Efficacy and Safety of Intravenous Remdesivir in Adult Patients with Severe Pneumonia caused by COVID-19 virus Infection: study protocol for a Phase 3 Randomized, Double-blind, Placebo-controlled, Multicentre trial

Horby PW. et al, (2020)